BMS Sees Another Setback As Milvexian Fails Phase III Test

Anticoagulant Once Projected To Be A $5bn Product

 
• By Mandy Jackson
  
A Phase III trial in acute coronary syndrome has been stopped, but atrial fibrillation is a larger market for milvexian (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Scrip

More from Clinical Trials